Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Inotiv Inc. (NOTV:NASDAQ), powered by AI.
Inotiv Inc. is currently trading at $0.39. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Inotiv Inc. on Alpha Lenz.
Inotiv Inc.'s P/E ratio is -0.2.
“Inotiv Inc. trades at a P/E of -0.2 (undervalued) with modest ROE of -44.8%.”
Ask for details →Inotiv Inc. is a prominent company specializing in contract research organization (CRO) services primarily aimed at enhancing drug discovery and development. The primary function of Inotiv is to provide comprehensive non-clinical and analytical services for pharmaceutical and biotechnology industries. These services play a critical role in the early stages of drug development, supporting the transition from discovery through clinical trials by ensuring safety and efficacy standards are met. Notably, Inotiv Inc. is involved in toxicology and pathology studies, bioanalysis, and consulting, all of which are crucial in advancing pharmaceutical research. The company’s significance in the market lies in its ability to streamline the drug development process for clients, potentially accelerating the timeline for bringing new therapies to market. Given the ever-evolving nature of medical research, Inotiv stands as a vital partner for clients seeking to navigate the complex regulatory environment while driving innovation in therapeutic solutions. Headquartered in the United States, Inotiv Inc. operates in one of the most dynamic sectors of the healthcare industry, supporting a global clientele with high-impact scientific expertise.
“Inotiv Inc. trades at a P/E of -0.2 (undervalued) with modest ROE of -44.8%.”
Ask for details →Inotiv Inc. (ticker: NOTV) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 1,977 employees. Market cap is $13M.
The current price is $0.39 with a P/E ratio of -0.18x and P/B of 0.09x.
ROE is -44.78% and operating margin is -7.21%. Annual revenue is $513M.